• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Iterum Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement

    6/11/25 7:15:25 AM ET
    $ITRM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ITRM alert in real time by email
    8-K
    0001659323false00-000000000016593232025-06-062025-06-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 06, 2025

     

     

    Iterum Therapeutics plc

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Ireland

    001-38503

    Not applicable

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    3 Dublin Landings

    North Wall Quay

     

    Dublin 1, , Ireland

     

    Not applicable

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: +353 1 6694820

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Ordinary Shares, par value $0.01 per share

     

    ITRM

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 1.01 Entry into a Material Definitive Agreement.

    On June 6, 2025, Iterum Therapeutics US Limited (“ITUS”), a subsidiary of Iterum Therapeutics plc (the “Company”), entered into a Product Commercialization Agreement (the “Agreement”) with EVERSANA Life Science Services, LLC (“Eversana”) for the commercialization of the Company’s approved product, ORLYNVAHTM. Pursuant to the Agreement, Eversana will provide sales and commercial operations services to ITUS in the United States, as well as the provision of marketing, logistics, channel management, regulatory, medical affairs and other services related to the commercialization of ORLYNVAHTM in the United States (the “Services”).

    Under the terms of the Agreement, ITUS will have legal, regulatory, and manufacturing responsibilities for ORLYNVAHTM, and will book sales for ORLYNVAHTM. The Agreement provides that Eversana shall ensure it complies with laws with respect to the provision of the Services for which it is responsible. ITUS will pay Eversana fees and reimburse Eversana for its expenses in performing the Services as agreed in applicable statements of work issued pursuant to the Agreement. Subject to the terms and conditions of the Agreement, Eversana will serve as the exclusive provider to ITUS of the Services agreed to between the parties in any statement of work issued pursuant to the Agreement.

    The term of the Agreement is from the date of execution until five years from the date of commercial launch of ORLYNVAHTM, subject to the rights of either party to terminate the Agreement as a result of a material breach by the other party, the insolvency of the other party, certain changes in law, the occurrence of certain safety recalls of ORLYNVAHTM, there being no active or uncompleted statements of work in effect pursuant to the Agreement, if there is a decline in net sales of ORLYNVAHTM in the United States over a specified period of time. Following a change of control of ITUS and/or the Company, ITUS, the change of control counterparty or the surviving entity may also terminate the Agreement, subject to the payment of specified fees to Eversana by the change of control counterparty or surviving entity. Eversana shall additionally have the right to terminate the Agreement if ITUS withdraws ORLYNVAHTM from the market in the United States for a specified period of time.

    The Agreement includes customary mutual obligations on the parties to protect and not disclose the confidential information and intellectual property of the other, and contains insurance, indemnification and limitation of liability provisions customary for service contracts of this type.

    The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which the Company intends to file as an exhibit to its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025.

     

     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    Iterum Therapeutics plc

     

     

     

     

    Date:

    June 11, 2025

    By:

    /s/ Corey N. Fishman

     

     

     

    Corey N. Fishman
    Chief Executive Officer

     


    Get the next $ITRM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITRM

    DatePrice TargetRatingAnalyst
    7/27/2021Sell → Hold
    Gabelli & Co.
    7/26/2021Buy → Neutral
    HC Wainwright & Co.
    More analyst ratings

    $ITRM
    SEC Filings

    See more
    • Iterum Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Iterum Therapeutics plc (0001659323) (Filer)

      6/11/25 7:15:25 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Iterum Therapeutics plc (0001659323) (Filer)

      5/19/25 7:15:09 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Iterum Therapeutics plc

      10-Q - Iterum Therapeutics plc (0001659323) (Filer)

      5/13/25 7:30:25 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum's newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducement grant exception as a component of new hire employment compensation. The share option was granted effective July 1, 2025, with an exercise price of $0.97 per share, which is equal to t

      7/2/25 4:30:00 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth

      DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) ("Iterum" or the "Company"), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the United States, as well as future commercialization activities across new products and markets. "We are delighted to welcome Christine to the Iterum leadership team at such a pivotal time for the company," said

      6/30/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence

      DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that NEJM Evidence published results from its REASSURE (REnewed ASsessment of Sulopenem in uUTI caused by Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin® (amoxicillin/clavulanate) in adult women with uncomplicated urinary tract infections (uUTIs) https://evidence.nejm.org/

      6/25/25 7:00:00 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Dunne Michael W. bought $35,000 worth of Ordinary Shares (25,000 units at $1.40), increasing direct ownership by 28% to 113,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      12/27/23 9:00:06 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunne Michael W. bought $18,442 worth of Ordinary Shares (10,000 units at $1.84), increasing direct ownership by 13% to 88,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      12/19/23 4:15:25 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dunne Michael W. bought $40,690 worth of Ordinary Shares (20,000 units at $2.03), increasing direct ownership by 34% to 78,754 units (SEC Form 4)

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      11/27/23 5:00:19 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Commercial Officer Coyne Christine

      4 - Iterum Therapeutics plc (0001659323) (Issuer)

      7/3/25 4:16:04 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Coyne Christine

      3 - Iterum Therapeutics plc (0001659323) (Issuer)

      7/3/25 4:15:09 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Whalen Joseph John

      3 - Iterum Therapeutics plc (0001659323) (Issuer)

      3/18/25 8:00:04 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Iterum Therapeutics upgraded by Gabelli & Co.

      Gabelli & Co. upgraded Iterum Therapeutics from Sell to Hold

      7/27/21 11:35:29 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics downgraded by HC Wainwright & Co.

      HC Wainwright & Co. downgraded Iterum Therapeutics from Buy to Neutral

      7/26/21 12:19:14 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Iterum Therapeutics upgraded by Gabelli & Co

      Gabelli & Co upgraded Iterum Therapeutics from Sell to Hold

      5/28/21 8:38:55 AM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITRM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Iterum Therapeutics plc

      SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)

      11/14/24 7:54:21 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Iterum Therapeutics plc

      SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

      11/14/24 3:31:48 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Iterum Therapeutics plc

      SC 13G - Iterum Therapeutics plc (0001659323) (Subject)

      1/31/24 4:55:45 PM ET
      $ITRM
      Biotechnology: Pharmaceutical Preparations
      Health Care